Positive surgical margins rate and EGFR [epidermal growth factor receptor] family members expression in prostate cancer treated with bicalutamide.
Phase of Trial: Phase II/III
Latest Information Update: 11 Oct 2007
At a glance
- Drugs Bicalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 11 Oct 2007 Status changed from discontinued to completed.
- 25 Jan 2007 New trial record.